Darolutamide dose optimization, 400 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 600 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 400 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, 600 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff
ORIC-944-01 is a first-in-human, open-label, multicenter phase 1/1b study with an interval 3+3 dose escalation design. Every cohort received rinzimetostat, alone or with an ARPI, and the study has no control arm. The primary endpoints of combination dose optimization are safety and the RP3D; rPFS, objective response rate, and duration of response are key secondary endpoints, and PSA and ctDNA are exploratory endpoints. The registry lists an estimated enrollment of 275 and an estimated primary completion in 2027-06.
Cohorts are small: 25 participants in single-agent dose escalation, 6 in the first apalutamide combination cohorts, 17 and then 20 in combination dose exploration, 18 at 400 mg and 15 at 600 mg in the post-abiraterone darolutamide dose-optimization cohorts, 19 in the post-androgen receptor inhibitor cohort, and 5 in the first food-effect report. The dose-exploration results pool participants who received apalutamide or darolutamide at 400 mg to 1,200 mg, and a footnote excludes three participants previously treated with lutetium 177, one of whom achieved a PSA50 response.
Follow-up is short: a median of 4.9 months in the 400 mg post-abiraterone cohort and 4.8 months in the post-androgen receptor inhibitor cohort. rPFS is reported as landmark rates; ORIC states that “Radiographic Progression-Free Survival Data Are Immature” and lists median rPFS as “Not mature”.
Endpoints of the 400 mg cohort come from different cutoffs and subsets: rPFS as of March 6, 2026 in 18 participants; PSA response at the January 16, 2026 clinical cutoff in 15 participants, excluding three without post-baseline PSA assessments; and ctDNA response in 14 participants (data on file as of March 11, 2026), excluding one without ctDNA at baseline and three without ctDNA data. Unconfirmed PSA responses are reported together with confirmed responses.
Baseline characteristics differed between the 400 mg and 600 mg post-abiraterone cohorts: median age 67 and 77 years, prior docetaxel 39% and 13%, and median baseline PSA 26 and 12 ng/mL. The exposure-response analysis used to select the RP3D pooled 113 participants from single-agent and combination cohorts.
All results are company-reported in press releases, investor presentations, and SEC filings. ORIC states that outcomes “may materially change as patient enrollment continues or more patient data become available”, that it may report unconfirmed responses and “interim analyses of only certain endpoints rather than all endpoints”, and that early clinical results “may not be predictive” of later-stage trials. ORIC’s comparisons with mevrometostat use competitor rPFS percentages “estimated from published data” and are labeled cross-trial.
Immature radiographic progression-free survival and early landmark analyses